{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:52:39Z","timestamp":1781653959023,"version":"3.54.5"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Kungliga Fysiografiska S\u00e4llskapet in Lund","award":["20161117"],"award-info":[{"award-number":["20161117"]}]},{"name":"Per-Eric och Ulla Schybergs Stiftelse","award":["20160413"],"award-info":[{"award-number":["20160413"]}]},{"name":"Ollie and Elof Ericssons Stiftelse","award":["20160908"],"award-info":[{"award-number":["20160908"]}]},{"DOI":"10.13039\/501100003173","name":"Crafoord Foundation","doi-asserted-by":"crossref","award":["20160643"],"award-info":[{"award-number":["20160643"]}],"id":[{"id":"10.13039\/501100003173","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006350","name":"Stiftelsen Clas Groschinskys Minnesfond","doi-asserted-by":"crossref","award":["M16 29"],"award-info":[{"award-number":["M16 29"]}],"id":[{"id":"10.13039\/501100006350","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006313","name":"Swedish Childhood Cancer Foundation","doi-asserted-by":"crossref","award":["PR2014-0059"],"award-info":[{"award-number":["PR2014-0059"]}],"id":[{"id":"10.13039\/501100006313","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006313","name":"Swedish Childhood Cancer Foundation","doi-asserted-by":"crossref","award":["TJ2014-0047"],"award-info":[{"award-number":["TJ2014-0047"]}],"id":[{"id":"10.13039\/501100006313","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.canlet.2017.07.019","type":"journal-article","created":{"date-parts":[[2017,7,26]],"date-time":"2017-07-26T18:01:45Z","timestamp":1501092105000},"page":"73-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Efficacy of the CDK inhibitor dinaciclib in\u00a0vitro and in\u00a0vivo in T-cell acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"405","author":[{"given":"Sausan A.","family":"Moharram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinjal","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Khanum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alissa","family":"Marh\u00e4ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohiuddin","family":"Gazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0719-5336","authenticated-orcid":false,"given":"Julhash U.","family":"Kazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2017.07.019_bib1","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","article-title":"Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2017.07.019_bib2","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1182\/asheducation-2014.1.174","article-title":"The genomic landscape of acute lymphoblastic leukemia in children and young adults","volume":"2014","author":"Mullighan","year":"2014","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.canlet.2017.07.019_bib3","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.1102160","article-title":"Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia","volume":"306","author":"Weng","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.canlet.2017.07.019_bib4","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1084\/jem.20070876","article-title":"FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors","volume":"204","author":"O'Neil","year":"2007","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.canlet.2017.07.019_bib5","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3324\/haematol.2008.005272","article-title":"Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia","volume":"94","author":"Baldus","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2017.07.019_bib6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/2159-8290.CD-15-0894","article-title":"Targeting CDK4 and CDK6: from discovery to therapy","volume":"6","author":"Sherr","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2017.07.019_bib7","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2016-10-706465","article-title":"The genetics and molecular biology of T-ALL,","volume":"129","author":"Girardi","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2017.07.019_bib8","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1002\/j.1460-2075.1996.tb00900.x","article-title":"Tal-1 induces T cell acute lymphoblastic leukemia accelerated by casein kinase IIalpha","volume":"15","author":"Kelliher","year":"1996","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2017.07.019_bib9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ccr.2012.02.013","article-title":"TLX homeodomain oncogenes mediate T cell maturation arrest in T-ALL via interaction with ETS1 and suppression of TCRalpha gene expression","volume":"21","author":"Dadi","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2017.07.019_bib10","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1038\/bcj.2015.80","article-title":"A\u00a0Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma","volume":"5","author":"Papayannidis","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.canlet.2017.07.019_bib11","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/nature08878","article-title":"Therapeutic antibody targeting of individual notch receptors","volume":"464","author":"Wu","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2017.07.019_bib12","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/leu.2011.130","article-title":"Redundancy and specificity of the metalloprotease system mediating oncogenic NOTCH1 activation in T-ALL","volume":"25","author":"Sulis","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2017.07.019_bib13","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood-2008-03-147967","article-title":"Notch signaling mediates G1\/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases","volume":"113","author":"Joshi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2017.07.019_bib14","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1016\/j.yexcr.2007.04.027","article-title":"Notch signaling induces SKP2 expression and promotes reduction of p27Kip1 in T-cell acute lymphoblastic leukemia cell lines","volume":"313","author":"Dohda","year":"2007","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.canlet.2017.07.019_bib15","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1158\/1078-0432.CCR-15-2869","article-title":"Synergistic drug combinations with a CDK4\/6 inhibitor in t-cell acute lymphoblastic leukemia","volume":"23","author":"Pikman","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2017.07.019_bib16","doi-asserted-by":"crossref","first-page":"12194","DOI":"10.18632\/oncotarget.14577","article-title":"ABL2 suppresses FLT3-ITD-induced cell proliferation through negative regulation of AKT signaling","volume":"8","author":"Kazi","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2017.07.019_bib17","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1007\/s00018-017-2494-0","article-title":"Tyrosine 842 in the activation loop is required for full transformation by the oncogenic mutant FLT3-ITD","volume":"74","author":"Kazi","year":"2017","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.canlet.2017.07.019_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.canlet.2017.01.035","article-title":"The dual specificity PI3K\/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL),","volume":"392","author":"Gazi","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2017.07.019_bib19","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/sj.leu.2404302","article-title":"Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast","volume":"20","author":"Graux","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2017.07.019_bib20","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1158\/1535-7163.MCT-16-0127","article-title":"Dinaciclib induces anaphase catastrophe in lung cancer cells via inhibition of cyclin-dependent kinases 1 and 2","volume":"15","author":"Danilov","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2017.07.019_bib21","doi-asserted-by":"crossref","first-page":"56864","DOI":"10.18632\/oncotarget.10870","article-title":"Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer","volume":"7","author":"Rajput","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2017.07.019_bib22","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/bjh.14285","article-title":"Pro-survival signal inhibition by CDK inhibitor dinaciclib in chronic lymphocytic leukaemia","volume":"175","author":"Chen","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2017.07.019_bib23","doi-asserted-by":"crossref","first-page":"29090","DOI":"10.1038\/srep29090","article-title":"Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity","volume":"6","author":"Chen","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2017.07.019_bib24","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1158\/0008-5472.CAN-15-1070","article-title":"The CDK9 inhibitor dinaciclib exerts potent apoptotic and antitumor effects in preclinical models of MLL-rearranged acute myeloid leukemia,","volume":"76","author":"Baker","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2017.07.019_bib25","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1158\/1535-7163.MCT-10-0324","article-title":"Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor","volume":"9","author":"Parry","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2017.07.019_bib26","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1158\/1078-0432.CCR-15-2869","article-title":"Synergistic drug combinations with a CDK4\/6 inhibitor in t-cell acute lymphoblastic leukemia","volume":"23","author":"Pikman","year":"2016","journal-title":"Clin. Cancer Res."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438351730455X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438351730455X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T18:20:06Z","timestamp":1656354006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030438351730455X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":26,"alternative-id":["S030438351730455X"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2017.07.019","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of the CDK inhibitor dinaciclib in\u00a0vitro and in\u00a0vivo in T-cell acute lymphoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2017.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}